Participated · Series A · Jul 2022

Piomic Medical develops a proprietary COMS therapy that combines concurrent optical and magnetic stimulation for hard-to-heal wounds and is delivered via the COMS One device. The therapy is designed to integrate into inpatient, ambulant and homecare settings and enables patient self-administration to support self-management. Following publication of its first-in-human multicenter prospective comparative trial in Swiss wound care centers, Piomic reported significant clinical benefits in therapy-refractory wounds. The company completed an initial soft launch in selected advanced wound care markets, with over 5,000 treatments performed and 450 patients treated, receiving strong customer feedback. Piomic recently closed an oversubscribed CHF 7.5M Series A to strengthen the body of evidence for clinical efficacy and pursue US market clearance. Proceeds will fund a large randomized controlled MAVERICKS trial focused on diabetic foot ulcers and support integration of COMS therapy with telemedicine for homecare delivery. Piomic develops an innovative non-invasive medical device for the treatment of chronic wounds. The company reported encouraging initial results from a clinical pilot trial and aims to provide clinical and economic benefits to institutions treating non-healing wounds. Management cites diabetes and an aging population as drivers of a market with more than 50 million patients affected by hard-to-heal wounds. Proceeds from the financing will be used to accelerate development of its advanced wound care product, expand the team and operations, and strengthen the clinical body of evidence for its core technology. Piomic has attracted continued support from existing business angels and a pool of private investors. The company also added Bertrand Hughes as a key advisor, bringing experience in advanced wound care and MedTech markets.

Participated · Seed · Jun 2020

Mobbot offers a mobile robotic and automation platform that prints concrete infrastructure directly at the final location, producing items such as cable chambers, retaining walls and beams. Its 3D‑concrete printing approach can produce parts up to twenty times faster and at forty percent lower cost than traditional fabrication, while cutting material waste and CO2 emissions by up to thirty percent. The company has demonstrated operational traction, delivering 40 concrete products to clients in a single day. Mobbot’s technology centers on a patented mobile robot and the startup plans to accelerate development and commercialization of that platform. The recently closed financing will support R&D and continuous product innovation as well as strengthen the marketing and sales organization. Agnès Petit is CEO and Founder; the company has also highlighted Thomas Ribeaud as CTO.

Participated · Seed · May 2019

Comphya develops CaverSTIM, an implantable neurostimulation system composed of a rechargeable implantable pulse generator and an electrode array to stimulate cavernous nerves and restore erectile function. The system is operated by clinician and patient controllers to tailor therapy and allow patient activation. Comphya is a 2017 spin-off from EPFL and is clinical-stage, with first-in-human data from Australia showing strong safety and efficacy signals and no reported infections or adverse events. The company reports a U.S. pilot study underway at Johns Hopkins following FDA IDE approval, and plans a pivotal U.S. clinical trial in 2026. Comphya aims to expand its Australian trial by recruiting additional patients and to fund the pivotal trial via a forthcoming Series B. Recent leadership updates include the appointment of Pim van Wesel as CEO in May 2025 to guide clinical growth and strategic execution. Comphya develops CaverSTIM, an implantable neurostimulation system composed of an implantable pulse generator and electrode arrays to activate nerves responsible for penile erection. The IPG is implanted subcutaneously in the lower abdomen and is remotely operated by clinician and patient controllers to tailor therapy and allow on‑demand activation. The company plans to use the newly raised funds to secure the start of pilot clinical trials in Q1 2023, which will assess safety and preliminary efficacy. Comphya is led by CEO Rodrigo Fraga‑Silva. The device targets patients who are non‑responsive to oral drugs and aims to restore erectile function via targeted neurostimulation. The company is based in Lausanne, Switzerland. Comphya develops CaverSTIM, an implantable neuroprosthetic device that stimulates the cavernosal nerve via external wireless controllers to restore natural penile erection for patients non-responsive to oral drugs. The technology targets spinal cord injury and post-prostatectomy patients who currently rely on intrapenile injections or penile implants. The company positions its solution as a physiological, less painful, and superior alternative to existing therapies. Comphya has participated in Venture Kick and Venture Leaders programs and was listed among the TOP100 Swiss startups. The recent bridge financing will fund the execution of pilot clinical trials planned to start in Q2 2021. Those pilot trials are intended to assess safety and preliminary efficacy and provide key clinical proof to advance the go-to-market process. Comphya is an EPFL spin-off developing a novel implantable neurostimulator intended to treat erectile dysfunction in patients who do not respond to oral drugs. The company’s core product is an implantable neurostimulator designed to offer a unique and superior treatment for an underserved market. Comphya announced a $3 million seed fundraising to complete product development and to fund a pilot clinical trial. The startup expects first clinical results in 2020. The seed round was led by investiere and joined by Zürcher Kantonalbank, the NEST pension fund and private investors. The company also appointed Steve Swinson as Chairman of the Board; he has held senior executive positions at GE and Medtronic.